

US009891223B2

(12) United States Patent

Beaulieu et al.

(10) Patent No.: US 9,891,223 B2

(45) **Date of Patent:** *Feb. 13, 2018

(54) METHOD OF ASSAYING LEUKOCYTE ELASTASE INHIBITOR FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER

(75) Inventors: Corinne Beaulieu, Rillieux la Pape (FR); Jean-Philippe Charrier, Tassin la Demi-Lune (FR); Genevieve Choquet-Kastylevsky, Francheville

(FR); Odile Mejan-Letourneur, Lyons (FR); Dominique Rolland, Saint Genis

les Ollieres (FR)

(73) Assignee: BIOMERIEUX, Marcy l'Etoile (FR)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 12/452,035

(22) PCT Filed: Jul. 10, 2008

(86) PCT No.: PCT/FR2008/051291

§ 371 (c)(1),

(2), (4) Date: Dec. 14, 2009

(87) PCT Pub. No.: WO2009/024691

PCT Pub. Date: Feb. 26, 2009

(65) Prior Publication Data

US 2010/0129828 A1 May 27, 2010

(30) Foreign Application Priority Data

Jul. 19, 2007 (FR) 07 05202

(51) **Int. Cl.**

 G01N 33/53
 (2006.01)

 G01N 30/72
 (2006.01)

 G01N 33/574
 (2006.01)

(52) U.S. Cl.

CPC . **G01N 33/57419** (2013.01); **G01N 2333/811** (2013.01)

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

4,529,931 5,002,870		7/1985 3/1991	Kuhns Leavitt et al.	
5,223,789	Α	6/1993	Katsuyama et al.	
5,344,760	A *	9/1994	Harvey	G01N 33/6872
				435/7.1
5,360,715	A	11/1994	Leavitt et al.	
6,001,632	A	12/1999	Braxton et al.	
6,291,205	B1	9/2001	Tuite et al.	
6 451 528	R1	9/2002	Carr et al	

2002/0160382	A1	10/2002	Lasek et al.
2003/0082533	A1	5/2003	Yue et al.
2003/0087818	A1	5/2003	Jiang et al.
2003/0109690	A1	6/2003	Ruben et al.
2003/0172388	A1	9/2003	Fujise et al.
2004/0157278	A1	8/2004	Astle et al.
2004/0191782	A1	9/2004	Wang
2004/0197930	A1*	10/2004	Rosenfeld et al 436/510
2005/0181398	A1	8/2005	Fung et al.
2005/0214826	A1	9/2005	Mor et al.
2006/0003359	A1	1/2006	Feinberg et al.
2006/0179496	A1	8/2006	Burgess et al.
2006/0205014	A1*	9/2006	Dotan G01N 33/569
			435/7.1
2007/0020707	A1	1/2007	Holten-Andersen et al.
2009/0239794	A1	9/2009	Soudevns et al.
2011/0104701	A1	5/2011	Ataman-Onal et al.
2005/0214826 2006/0003359 2006/0179496 2006/0205014 2007/0020707 2009/0239794	A1 A1 A1 A1* A1	9/2005 1/2006 8/2006 9/2006 1/2007 9/2009	Mor et al. Feinberg et al. Burgess et al. Dotan

FOREIGN PATENT DOCUMENTS

AΤ	500 719 A1	3/2006
CN	1396182 A	2/2003
EP	0 496 174 A1	7/1992
EP	1 724 586 A2	11/2006
EP	1 775 590 A1	4/2007
FR	2 581 456 A1	11/1986
JP	2-287266 A	11/1990
JP	4-64068 A	2/1992
JP	2001-069971 A	3/2001
WO	95/16462 A1	6/1995
WO	WO 00/33083 A1	6/2000
WO	WO 00/50588 A2	8/2000
WO	01/31019 A2	5/2001
WO	01/071357 A2	9/2001
WO	WO 02/20731 A1	3/2002
	(Cor	tinued)

OTHER PUBLICATIONS

Friedman et al., Proteomics 2004, 4, 793-811.* Giusti et al., Proteomics May 2007, 7(10): 1634-1643.* Guo et al., J Mol. Med., 2004, 82:768-774.*

Kim et al., Annals Clin. Lab. Sci. 2003, 33(1): 32-38.* May 13, 2011 Restriction and Election of Species Requirement

issued in U.S. Appl. No. 12/452,038. Sep. 1, 2011 Office Action issued in U.S. Appl. No. 12/452,038. Nov. 16, 2011 Election of Species Requirement issued in U.S. Appl.

No. 12/452,037. Sep. 15, 2011 Restriction and Election of Species Requirement issued in U.S. Appl. No. 12/452,042.

Oct. 28, 2011 Office Action issued in U.S. Appl. No. 12/452,042. Aug. 1, 2011 Restriction and Election of Species Requirement issued in U.S. Appl. No. 12/452,034.

Oct. 27, 2011 Office Action issued in U.S. Appl. No. 12/452,034. Oct. 28, 2011 Restriction Requirement issued in U.S. Appl. No. 12/452,047.

(Continued)

Primary Examiner — Hong Sang (74) Attorney, Agent, or Firm — Oliff PLC

(57) **ABSTRACT**

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Leukocyte Elastase Inhibitor tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.



(56)References Cited

FOREIGN PATENT DOCUMENTS

WO	WO 03/065003 A2	8/2003
WO	WO 03/087831 A2	10/2003
WO	WO 2004/073730 A1	9/2004
WO	WO 2005/015218 A1	2/2005
WO	WO 2005/015219 A1	2/2005
WO	WO 2005/015226 A1	2/2005
WO	WO 2005015218 A1 *	2/2005
WO	WO 2005015219 A1 *	2/2005
WO	05/035003 A2	4/2005
WO	05/060996 A2	7/2005
WO	WO 2005/083440 A2	9/2005
WO	WO 2006/015079 A2	2/2006
WO	WO 2006/074360 A2	7/2006
WO	WO 2007/002535 A2	1/2007
WO	WO 2007/005578 A1	1/2007
WO	WO 2007020522 A2 *	2/2007
WO	WO 2007/068985 A2	6/2007
WO	WO 2007/140352 A2	12/2007
WO	WO 2008/021290 A2	2/2008
WO	WO 2008/028968 A2	3/2008
WO	WO 2008/036981 A1	3/2008

OTHER PUBLICATIONS

SCORE sequence search result #1, Geneseq Database, "20110423_ 191537_us-12-452-038-2.rag" Apr. 23, 2011.

Bruce et al., Cancer-Wide Tissue Microanay Survey of Ezrin and Merlin Expression, Proc Amer Assoc Cancer Res, vol. 46, Abstract #424, 2005.

Gould et al., "cDNA Cloning and Sequencing of the Protein-Tyrosine Kinase Substrate, Ezrin, Reveals Homology to Band 4.1," The EMBO Journal, vol. 8, No. 13, pp. 4133-4142, 1989.

Etzioni et al., "The Case for Early Detection," Nature Review, vol. 3, Internet pp. 1-10, Apr. 2003.

Mercer, "Use of Multiple Markers to Enhance Clinical Utility," Immunol Ser., vol. 53, pp. 39-54, 1990.

Delanote et al., "Plastins: Versatile Modulators of Actin Organization in (patho)physiological Cellular Processes," A Pharmacologica Sinica, vol. 26, No. 7, pp. 769-779, Jul. 2005. Hasselblatt et al., "Identification of Novel Diagnostic Markers for

Choroid Plexus Tumors," Am. J. Surg Pathol, vol. 30, No. 1, pp. 66-74, Jan. 2006.

Lin et al., "Identification of I-Plastin, a Human Fimbrin Isoform Expressed in Intestine and Kidney," Molecular and Cellular Biology, vol. 14, No. 4, pp. 2457-2467, Apr. 1994.
Carroll et al., "Liver Fatty Acid-Binding Protein: A Marker for

Studying Cellular Differentiation in Gut Epithelial Neoplasms," Gastroenterology, vol. 99, pp. 1727-1735, 1999.

Kayser et al., "Primary Colorectal Carcinomas and their Intrapulmonary Metastases: Clinical, Glyco-, Immuno- and Lectin Histochemical, Nuclear and Syntactic Structure Analysis with Emphasis on Correlation with Period of Occurrence of Metastases and Survival," APMIS, vol. 110, pp. 435-446, 2002.

Kuusela et al., "Comparison of CA 19-9 and Carcinoembryonic Antigen (CEA) Levels in the Serum of Patients with Colorectal Diseases," Br. J. Cancer, vol. 49, pp. 135-139, 1984.

Pelsers et al., "Fatty Acid-Binding Proteins as Plasma Markers of Tissue Injury," Clinica Chimica Acta, vol. 352, pp. 15-35, 2005. Iurisci et al., "Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients," Clinical Cancer Research, vol. 6, pp. 1389-1393, Apr. 2000.

Niederkofler et al., "Novel Mass Spectrometric Immunoassays for the Rapid Structural Characterization of Plasma Apolipoproteins," Journal of Lipid Research, vol. 44, pp. 630-639, 2003.

Hortin, "The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Pepetidome," Clinical Chemistry, vol. 52, No. 7, pp. 1223-1237, 2006.

Hachem, "Serum Apolipoproteins A-I, A-II and B in Hepatic Metastases Comparison with other Liver Diseases: Hepatomas and

Remold-O'Donnell et al., "Sequence and Molecular Characterization of Human Monocyte/Neutrophil Elastase Inhibitor," Proc. Natl. Acad. Sci. vol. 89, pp. 5635-5639, Jun. 1992.

Cooley et al., "The Serpin MNEI Inhibits Elastase-Like and Chymotrypsin-Like Proteases through Efficient Reactions at Two Active Sites," Biochemistry, vol. 40, pp. 15762-15770, 2001.

Algrain et al, "Ezrin Contains Cytoskeleton and Membrane Binding Domains Accounting for its Proposed Role as a Membrane-Cytoskeletal Linker," The Journal of Cell Biology, vol. 120, No. 1, pp. 129-139, Jan. 1993.

Jiang et al., "Cytokine Regulation of Ezrin Expression in the Human Colon Cancer Cell Line HT29," Anticancer Research, vol. 16, pp. 861-866, 1996.

Hiscox et al, "Ezrin Regulates Cell-Cell and Cell-Matrix Adhesion, A Possible Role with E-Cadherin/β-Catenin," Journal of Cell Science, vol. 112, pp. 3081-3090, 1999.

Xiao et al., "An Approach to Studying Lung Cancer-Related Proteins in Human Blood," Molecular & Cellular Proteomics, vol. 4, pp. 1480-1486, 2005.

Anders et al., "Aminoacyclases," Advances in Pharmacology, vol. 27, pp. 431-448, 1994.

Lorentz et al., "A New Method for the Assay of Aminoacylase: Elaboration of a Fixed-Incubation Method for Routine Measurements," Clinics Chimica Acta, vol. 63, pp. 263-269, 1975

Lorentz et al, "Clinical Application of a New Method for the Determination of Aminoacylase in Human Serum," Clinica Chimica Acta, vol. 63, pp. 271-274, 1975.

Cook et al, "Human Aminoacylase-1," The Journal of Biological Chemistry, vol. 268, No. 23, pp. 17010-17017, 1993.

Miller et al., "Lack of Expression of Aminoacylae-1 in Small Cell Lung Cancer," The Journal of Clinical Investigation, Inc., vol. 83, pp. 2120-2124, Jun. 1989.

Balabanov et al., "Tumour-Related Enzyme Alterations in the Clear Cell Type of Human Renal Cell Carcinoma Identified by Twodimensional Gel Electrophoresis," Eur. J. Biochem., vol. 268, pp. 5977-5980, 2001.

Chan et al, "Human Liver Fatty Acid Binding Protein cDNA and Amino Acid Sequence," The Journal of Biological Chemistry, vol. 260, No. 5, pp. 2629-2632, 1985.

Das et al., "Expression Pattern of Fatty Acid-Binding Proteins in Human Normal and Cancer Prostate Cells and Tissues," Clinical Cancer Research, vol. 7, 1706-1715, Jun. 2001.

Stulik et al., "Proteome Study of Colorectal Carcinogenesis," Electrophoresis, vol. 22, pp. 3019-3025, 2001.

Yamazaki et al., "Liver Fatty Acid-Binding Protein is a New Prognostic Factor for Hepatic Resection of Colorectal Cancer Metastases," Journal of Surgical Oncology, vol. 72, pp. 83-87, 1999. Sweetser et al., "The Human and Rodent Intestinal Fatty Acid Binding Protein Genes," The Journal of Biological Chemistry, vol. 262, No. 33, pp. 16060-16071, 1987.

Pelsers et al, "Intestinal-Type and Liver-Type Fatty Acid-Binding Protein in the Intestine. Tissue Distribution and Clinical Utility", Clinical Biochemistry, vol. 36, pp. 529-535, 2003.

Xiao et al, "Dietary Exposure to Soy or Whey Proteins Alters Colonic Global Gene Expression Profiles During Rat Colon Tumorigenesis," Molecular Cancer, vol. 4, No. 1, pp. 1-17, Jan. 11,

Engwegen et al., "Identification of Serum Proteins Discriminating Colorectal Cancer Patients and Healthy Controls Using Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry," World J. Gastrenterol, vol. 12, No. 10, pp. 1536-1544, Mar. 14, 2006.

Zhang et al., "Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer," Cancer Research, vol. 64, pp. 5882-5890, Aug. 15, 2004.

Lin et al., "Human Plastin Genes," The Journal of Biological

Chemistry, vol. 268, No. 4, pp. 2781-2792, 1993. Lavabre-Bertrand et al., "Plasma Proteasome Level is a Potential Marker in Patients with Solid Tumors and Hemopoietic Malignancies," Cancer, vol. 92, No. 10, pp. 2493-2500, Nov. 15, 2001

Schwartz, "Enzymes as Prognostic Markers and Therapeutic Indi-



(56) References Cited

OTHER PUBLICATIONS

McCool et al., "Roles of Calreticulin and Calnexin During Mucin Synthesis in LS180 and HT29/A1 Human Colonic Adenocarcinoma Cells," Biochem. J., vol. 341, pp. 593-600, 1999.

Motoo et al., "Serum Levels of Pancreatitis-Associated Protein in Digestive Diseases with Special Reference to Gastrointestinal Cancer," Digestive Diseases and Sciences, vol. 44, No. 6, pp. 1142-1147, Jun. 1999.

Abe et al., "Preparation of Recombinant MK-1/EP-CAM and Establishment of an ELISA System for Determining Soluble MK-1/EP-CAM Levels in Sera of Cancer Patients," Journal of Immunological Methods, vol. 270, pp. 227-233, 2002.

Katayama et al., "Soluble E-Cadherin Fragments Increased in Circulation of Cancer Patients," Br. J. Cancer, vol. 69, pp. 580-585, 1994.

Wilmanns et al., "Soluble Serum E-Cadherin as a Marker of Tumour Progression in Colorectal Cancer Patients," Clinical & Experimental Metastasis, vol. 21, pp. 75-78, 2004.

Gold et al., "Specific Carcinoembryonic Antigens of the Human Digestive System," J. Exp. Med., pp. 467-481, 1965.

Kim et al., "Gastrointestinal Tract Cancer Screening Using Fecal Carcinoembryonic Antigen," Annals of Clinical & Laboratory Science, vol. 33, No. 1, pp. 32-38, 2003.

Holmgren et al., "Detection by Monoclonal Antibody of Carbohydrate Antigen CA 50 in Serum of Patients with Carcinoma," British Medical Journal, vol. 288, pp. 1479-1482, May 19, 1984.

Klug et al., Monoclonal Anitbody Immunoradiometric Assay for An Antigenic Determinant (CA 72) on a Novel Pancarcinoma Antigen (TAG-72), Int. J. Cancer, vol. 38, pp. 661-669, 1986.

Holland et al., "Testosterone Serica: Posible Marcador En El Cancer Colorrectal," Medicine (Buenos Aires), vol. 53, pp. 117-123, 1993. Model et al., "Detection of Methylated DNA in Plasma from Colorectal Cancer Patients and Controls by Real-Time PCR Analysis of Septin 9," World Congress on Gastrointestinal Cancer, Jul. 2006

Ebert et al., "Aristaless-like Homeobox-4 Gene Methylation is a Potential Marker for Colorectal Adenocarcinomas," Gastroenterology, vol. 131, pp. 1418-1430, 2006.

Bianco et al., "Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer," Clin. Cancer Res., vol. 12, No. 17, pp. 5158-5164, Sep. 1, 2006.

Mori et al., "Two-Dimensional Electrophoresis Database of Fluorescence-Labeled Proteins of Colon Cancer Cells," Journal of Chromatography B, vol. 823, pp. 82-97, 2005.

Duffy et al., "Tumour Markers in Colorectal Cancer: European Group on Tumour Markers (EGTM) Guidelines for Clinical Use," European Journal of Cancer, vol. 43, pp. 1348-1360, 2007.

Rouzier et al., "Immunocytochemical Detection of Bone Marrow Micrometastases in Colorectal Carcinoma Patients, Using A Monoclonal Antibody to Villin," Cytometry (Communications in Clinical Cytometry), vol. 46, pp. 281-289, 2001.

Nishizuka et al., "Diagnostic Markers that Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling," Cancer Research, vol. 63, pp. 5243-5250, Sep. 1, 2003.

Wang et al., Proteomic Dissection of the Molecular Mechanisms Underlying Hepatic Metastasis in Colorectal Cancer, XP009093529, Database Accession No. PREV200600505326, AGA Abstracts, p. A-676, W1533, Apr. 2006.

Mori et al., A Genome-Wide Search Identifies Epigenetic Silencing of Somatostatin, Tachykinin-1, and 5 other Genes in Colon Cancer, Gastroenterology, vol. 131, pp. 797-808, 2006.

Database WPI Week 200777, Thomson Scientific, London, GB; AN 2007-817830, XP002464797 & CN 1 967 246 (Proteome Analysis Research Center) May 23, 2007, Abstract.

Fujiwara et al., Global Gene Expression Analysis of Rat Colon Cancers Induced by a Food-Borne Carcinogen, 2-amino-1-methylDorudi et al., "E-Cadherin Expression in Colorectal Cancer," American Journal of Pathology, vol. 142, No. 4, pp. 981-986, Apr. 1993

Lawrie et al., "Liver Fatty Acid Binding Protein Expression in Colorectal Neoplasia," British Journal of Cancer, vol. 90, pp. 1955-1960, 2004.

Mar. 18, 2009 International Search Report Issued in International Application No. PCT/FR2008/051291.

Feb. 23, 2009 International Search Report Issued in International Application No. PCT/FR2008/051289.

Feb. 18, 2009 International Search Report Issued in International Application No. PCT/FR2008/051295.

Jan. 16, 2009 International Search Report Issued in International Application No. PCT/FR2008/051298.

Mar. 27, 2009 International Search Report Issued in International Application No. PCT/FR2008/051290.

Mar. 6, 2009 International Search Report Issued in International Application No. PCT/FR2008/051293.

Mar. 5, 2009 International Search Report Issued in International Application No. PCT/FR2008/051292.

U.S. Appl. No. 12/452,038, filed Dec. 14, 2009, in the name of Monique Arpin et al.

U.S. Appl. No. 12/452,037, filed Dec. 14, 2009, in the name of Yasemin Ataman-Onal et al.

U.S. Appl. No. 12/452,042, filed Dec. 14, 2009, in the name of Monique Arpin et al.

U.S. Appl. No. 12/452,048, filed Dec. 14, 2009, in the name of Jean-Philippe Charrier et al.

U.S. Appl. No. 12/452,034, filed Dec. 14, 2009, in the name of Yasemin Ataman-Onal et al.

U.S. Appl. No. 12/452,047, filed Dec. 14, 2009, in the name of Yasemin Ataman-Onal et al.

Kaetzel et al.; "Protein disulphide-isomerase from human placenta and rat liver—Purification and immunological characterization with monoclonal antibodies;" *Biochem. J.*; 1987; pp. 39-47; vol. 241, No. 1: Great Britain

Kozaki et al.; "Tissue Distribution of Erp61 and Association of Its Increased Expression with IgG Production in Hybridoma Cells;" *Experimental Cell Research*; 1994; pp. 348-358; vol. 213, No. 2; Academic Press, Inc.

Leys et al.; "Expression and prognostic significance of prothymosin- α and Erp57 in human gastric cancer;" *Surgery*; 2007; pp. 41-50; vol. 141, No. 1; Mosby Co.; St. Louis, MO, U.S.A.

International Search Report dated Nov. 25, 2009 in International Application No. PCT/FR2009/051361 (with translation).

Feb. 12, 2009 International Search Report Issued in International Application No. PCT/FR2008/051294.

Feb. 3, 2012 Office Action issued in U.S. Appl. No. 12/452,048. Feb. 1, 2012 Office Action issued in U.S. Appl. No. 12/452,037.

Jan. 9, 2012 Office Action issued in U.S. Appl. No. 12/452,047.

Otsuka et al. "Differential Expression of L-Plastin Gene in Human Colorectal Cancer Progression and Metastasis," Biochemical and Biophysical Research Communications, vol. 289, No. 4, pp. 876-881, 2001.

Sass et al., "Mutations in ACY1, the Gene Encoding Aminoacylase 1, Cause a Novel Inborn Error of Metabolism", The American Journal of Human Genetics, Mar. 2006, vol. 78, pp. 401-409.

Tockman et al., "Considerations in Bringing a Cancer Biomarker to Clinical Application", Cancer Research, May 1, 1992, vol. 52, pp. 2711s-2718s.

Freeman et al., "APO-AII is an Elevated Biomarker of Chronic Non-Human Primate Ethanol Self-Administration", Alcohol & Alcoholism, Mar. 2006, vol. 41, No. 3, pp. 300-305.

Stierum et al.; Proteome analysis reveals novel proteins associated with proliferation and differentiation of colorectal cancer cell line Caco-2; *Biochemica et Biophysica Acta*; 2003; pp. 73-91; vol. 1650, No. 1-2.

Elsevier Publishing, "Human PDIA1 tryptic peptide—SEQ ID 33;" Retrieved from EBI accession No. GSP:ASS06881; Database Accession No. ASS06881, 2003.

Apr. 23, 2014 Office Action issued in U.S. Appl. No. 13/712,340.



(56) References Cited

OTHER PUBLICATIONS

Jun. 12, 2012 Office Action issued in U.S. Appl. No. 12/452,042. Jun. 18, 2012 Office Action issued in U.S. Appl. No. 12/452,047. Davies et al., "Loss of Cellular Distribution of Ezrin in Human Colon Cancer", ASCO 2006, Gastrointestinal Cancers Symposium, 2006 Abstract 322.

Mahipal et al., "Epidermal Growth Factor Receptor Overexpression in Resected Pancreatic Cancer", J Clinical Oncology, 2011, 29: suppl 4; Abstract 317.

Brattstrom et al., "HER-2 overexpression in patients with esophageal carcinoma correlates with poorer survival", ASCO 2005 Gastrointestinal Cancers Symposium, 2005, Abstract 63.

Kavanagh et al., "Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?" BMC Cancer, Jan. 1, 2009, 9:1-6. Jun. 18, 2013 Office Action issued in U.S. Appl. No. 12/452,037. Jul. 31, 2012 Office Action issued in U.S. Appl. No. 12/452,048. Jul. 24, 2012 Restriction Requirement issued in U.S. Appl. No. 12/999,242.

Aug. 3, 2012 Office Action issued in U.S. Appl. No. 12/452,037. Dec. 28, 2012 Office Action issued in U.S. Appl. No. 12/452,037. Jan. 30, 2014 Office Action issued in U.S. Appl. No. 12/452,034. Sep. 30, 2013 Office Action issued in U.S. Appl. No. 12/452,034. Oct. 15, 2013 Office Action issued in U.S. Appl. No. 12/452,037. Sep. 10, 2014 Office Action issued in U.S. Appl. No. 13/732,521. Sep. 19, 2014 Office Action issued in U.S. Appl. No. 13/712,340. Aug. 1, 2014 Office Action issued in U.S. Appl. No. 12/452,034. Jeck et al., "Local Ischemia Causes Carcinoma-Like Changes of the Rectum", Dis Colon Rectum., 1996, vol. 39, No. 9, pp. 1026-1030 (obstract only)

Jul. 24, 2014 Office Action issued in U.S. Appl. No. 12/452,047. Kozak et al., "Characterization of Serum Biomarkers for Detection of Early Stage Ovarian Cancer", *Proteomics*, 2005, vol. 5, pp. 4589-4596.

Bury et al., "Quantification of Human Serum Apolipoprotein Al by Enzyme Immunoassay", *Clinical Chemistry*, 1985, vol. 31, No. 2, pp. 247-251.

Laine, Anne, "Rocket Immunoelectrophoresis Technique or Electroimmunodiffusion", Methods in Molecular Biology, 1992, vol. 10, pp. 201-205.

Apr. 9, 2015 Office Action issued in U.S. Appl. No. 13/732,521. Mar. 6, 2015 Office Action issued in U.S. Appl. No. 12/452,034. Feb. 23, 2015 Office Action issued in U.S. Appl. No. 12/452,047. Majander-Nordenswan et al., "Genomic Structure of the Human Ezrin Gene," Human Genetics, vol. 103, 1998, pp. 662-665. Sep. 8, 2015 Office Action issued in U.S. Appl. No. 14/701,002. Dec. 3, 2015 Office Action issued in U.S. Appl. No. 12/452,034. Intestinal Ischemia Causes, Mayo Clinic, http://www.mayoclinic.org/diseases-conditions/intestinal-ischemia/basics/causes/con-20023818, accessed Nov. 9, 2015.

Dec. 31, 2015 Office Action issued in U.S. Appl. No. 13/732,521. Abaza et al., "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444.

Harig et al., "Induction of Cytotoxic T-cell Responses Against Immunoglobulin V region-Derived Peptides Modified at Human Leukocyte Antigen-A2 Binding Residues," Blood, vol. 98, pp. 2999-3005, 2001.

Jan. 11, 2016 Office Action issued in U.S. Appl. No. 13/712,340. Jul. 15, 2015 Office Action issued in U.S. Appl. No. 13/712,340. Guo et al. "Combined Use of Positive and Negative Immunomagnetic Isolation Followed By Real-Time RT-PCR for Detection of the Circulating Tumor Cells in Patients with Colorectal Cancers." J Mol. Med., 2004, 82:768-774.

Aug. 5, 2015 Office Action issued in U.S. Appl. No. 12/452,047. Mar. 24, 2016 Office Action Issued in U.S. Appl. No. 14/701,002. Mar. 3, 2016 Office Action issued in U.S. Appl. No. 12/452,047. May 25, 2016 Office Action issued in U.S. Appl. No. 12/452,034. Jul. 25, 2016 Office Action issued in U.S. Appl. No. 13/712,340. Sep. 21, 2016 Office Action Issued in U.S. Appl. No. 14/701,002. Sep. 20, 2016 Office Action Issued in U.S. Appl. No. 12/452,047. Hogle, Doreen M. et al. "Quantitation of Plasma Apolipoprotein A—I Using Two Monoclonal Antibodies in an Enzyme-Linked Immunosorbent Assay." Journal of Lipid Research, vol. 29, pp. 1221-1229, 1988.

Mar. 15, 2017 Office Action issued in U.S. Appl. No. 13/712,340. The 1000 Genomes Project Consortium. "A Map of Human Genome Variation from Population-Scale Sequencing." Nature, 2010, vol. 467, pp. 1061-1073.

Apr. 4, 2017 Office Action issued in U.S. Appl. No. 12/452,047. Shin et al.; "Global Profiling of the Cell Surface Proteome of Cancer Cells Uncovers an Abundance of Proteins with Chaperone Function;" *The Journal of Biological Chemistry*; Feb. 28, 2003; pp. 7607-7616; vol. 278, No. 9; The American Society for Biochemistry and Molecular Biology, Inc.; U.S.A.

Tomonaga et al.; "Identification of Altered Protein Expression and Post-Translational Modifications in Primary Colorectal Cancer by Using Agarose Two-Dimensional Gel Electrophoresis;" *Clinical Cancer Research*; vol. 10, Mar. 15, 2005; pp. 2007-2014.

Stierum et al.; Proteome analysis reveals novel proteins associated with proliferation and differentiation of colorectal cancer cell line Caco-2; *Biochemica et Biophysica Acta*; 2003; pp. 73-91; vol. 1650, No. 1-2; Elsevier Publishing "Human PDIA1 tryptic peptide—SEQ ID 33;" Retrieved from EBI accession No. GSP:ASS06881; Database Accession No. ASS06881, 2003.

* cited by examiner







Figure 1





DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

